2018
Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies
Dobry AS, Zogg CK, Hodi FS, Smith TR, Ott PA, Iorgulescu JB. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Cancer Immunology, Immunotherapy 2018, 67: 1833-1844. PMID: 30191256, PMCID: PMC6249064, DOI: 10.1007/s00262-018-2241-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalComorbidityDisease ManagementFemaleHealth Care SurveysHumansImmunotherapyMaleMelanomaMiddle AgedMolecular Targeted TherapyNeoplasm StagingOdds RatioProtein Kinase InhibitorsProto-Oncogene Proteins B-rafRegistriesSymptom AssessmentUnited StatesYoung AdultConceptsStage 4 melanomaOverall survivalInitial approvalCutaneous melanomaLandmark survival analysisSubstantial clinical efficacyImproved overall survivalMetastatic cutaneous melanomaNational Cancer DatabaseStage 4 diseaseCheckpoint blockade immunotherapySurvival of patientsRisk-adjusted analysisBlockade immunotherapyCheckpoint blockadeNovel immunotherapiesMultivariable analysisClinical efficacyMetastatic melanomaNational cohortCancer DatabaseUninsured patientsClinical trialsPatientsSurvival analysisImproved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort
Iorgulescu JB, Harary M, Zogg CK, Ligon KL, Reardon DA, Hodi FS, Aizer AA, Smith TR. Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunology Research 2018, 6: 1039-1045. PMID: 30002157, PMCID: PMC6230261, DOI: 10.1158/2326-6066.cir-18-0067.Peer-Reviewed Original ResearchConceptsMelanoma brain metastasesCheckpoint blockade immunotherapyMBM patientsOverall survivalBlockade immunotherapyStage 4 melanomaNational Cancer DatabaseManagement of patientsKaplan-Meier techniqueLarge national cohortEarly clinical trialsBrain metastasesExtracranial metastasesSurvival benefitAdvanced melanomaOS improvementNational cohortCancer DatabaseClinical trialsNovel therapiesU.S. cancerPatientsTherapy trialsProportional hazardsFDA approvalEthnic disparity in primary cutaneous CD30+ T‐cell lymphoproliferative disorders: an analysis of 1496 cases from the US National Cancer Database
Su C, Nguyen KA, Bai HX, Zogg CK, Cao Y, Karakousis G, Zhang PJ, Zhang G, Xiao R. Ethnic disparity in primary cutaneous CD30+ T‐cell lymphoproliferative disorders: an analysis of 1496 cases from the US National Cancer Database. British Journal Of Haematology 2018, 181: 752-759. PMID: 29676444, DOI: 10.1111/bjh.15222.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedDatabases, FactualDisease-Free SurvivalFemaleFollow-Up StudiesHead and Neck NeoplasmsHumansKi-1 AntigenLymphoproliferative DisordersMaleMiddle AgedNeoplasm ProteinsRetrospective StudiesSex FactorsSkin NeoplasmsSocioeconomic FactorsSurvival RateT-LymphocytesUnited StatesConceptsT-cell lymphoproliferative disorderUS National Cancer DatabaseNational Cancer DatabasePrimary cutaneous CD30Overall survivalShorter overall survivalCutaneous CD30AA patientsLymphoproliferative disordersDisease characteristicsCancer DatabaseCutaneous T-cell lymphoma casesCox proportional hazards regression analysisPrimary cutaneous T-cell lymphomaEthnic disparitiesHigher Charlson-Deyo scoreProportional hazards regression analysisCutaneous T-cell lymphomaT-cell lymphoma casesCharlson-Deyo scorePrimary disease siteReceipt of chemotherapyHazards regression analysisSmall retrospective studiesHigher clinical stage
2017
Epidemiology of malignant cutaneous granular cell tumors: A US population-based cohort analysis using the Surveillance, Epidemiology, and End Results (SEER) database
Mirza FN, Tuggle CT, Zogg CK, Mirza HN, Narayan D. Epidemiology of malignant cutaneous granular cell tumors: A US population-based cohort analysis using the Surveillance, Epidemiology, and End Results (SEER) database. Journal Of The American Academy Of Dermatology 2017, 78: 490-497.e1. PMID: 28989104, PMCID: PMC5815907, DOI: 10.1016/j.jaad.2017.09.062.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBlack or African AmericanChildFemaleGranular Cell TumorHumansIncidenceKaplan-Meier EstimateKidney NeoplasmsMaleMiddle AgedNeoplasm StagingPancreatic NeoplasmsResidence CharacteristicsRetrospective StudiesSEER ProgramSex FactorsSkin NeoplasmsSurvival RateUnited StatesWhite PeopleYoung AdultConceptsDisease-specific survivalCutaneous granular cell tumorsPopulation-based cohort analysisEnd Results (SEER) databaseMedian survival timeGranular cell tumorSurgical resectionResults databaseCell tumorsCohort analysisSurvival timeCox proportional hazards regressionPoor disease-specific survivalRisk-adjusted associationHigh-risk patientsEnd Results (SEER) dataProportional hazards regressionSingle-institution studyAdvanced cancer stageRisk-adjusted modelsDSS ratesOverall survivalPatient characteristicsSubstantial morbiditySecondary malignancies
2016
Survival outcomes after prolonged intensive care unit length of stay among trauma patients: The evidence for never giving up
Kisat MT, Latif A, Zogg CK, Haut ER, Zafar SN, Hashmi ZG, Oyetunji TA, Cornwell EE, Zafar H, Haider AH. Survival outcomes after prolonged intensive care unit length of stay among trauma patients: The evidence for never giving up. Surgery 2016, 160: 771-780. PMID: 27267552, DOI: 10.1016/j.surg.2016.04.024.Peer-Reviewed Original ResearchConceptsIntensive care unit lengthICU LOSInjury Severity ScoreGlasgow Coma ScaleTrauma patientsRace/ethnicityComa ScaleSeverity scoreNon-Hispanic black race/ethnicityHigh mortalityNational Trauma Data BankBlack race/ethnicityCritical care supportProlonged ICU LOSAdult ICU patientsAdult trauma patientsEmergency department dispositionMultivariable logistic regressionTrauma Data BankClustering of patientsHospital complicationsICU stayVentilator dependencyOverall survivalRenal failure